Shares of Eli Lilly have declined -4.7% over the year-to-date period against the Zacks Large Cap Pharmaceuticals industry's decline of -0.6%. Declining sales of Trulicity, rising pricing pressure on some drugs, and potential competition in the GLP-1 diabetes/obesity market are some of Eli Lilly's top-line headwinds. Lilly is making rapid pipeline progress in obesity and diabetes. However, data from phase III studies on its weight-loss pill, orforglipron, was mixed.